A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
This study will have two 16‐day treatment periods (four escalating doses or matching placebo at four days interval) separated by a 10 to 14‐day washout period. There will be a 14‐day follow‐up period.
Epistemonikos ID: 3a023835330543b3d443a626b4ff9705ae726656
First added on: May 22, 2024